3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.
PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION
申请人:Feenstra W. Roelof
公开号:US20070142397A2
公开(公告)日:2007-06-21
The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine-D
2
receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect.
The compounds have the general formula (1):
wherein the symbols have the meanings given in the specification.
ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION
申请人:Solvay Pharmaceuticals B.V.
公开号:EP1827427B1
公开(公告)日:2008-07-23
[EN] PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION<br/>[FR] DERIVES DE PHENYLPIPERAZINE PRESENTANT UN AGONISME PARTIEL DES RECEPTEURS D2 DE LA DOPAMINE COMBINE A UNE INHIBITION DU RECAPTAGE DE LA SEROTONINE
申请人:SOLVAY PHARM BV
公开号:WO2006061379A1
公开(公告)日:2006-06-15
[EN] The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification. [FR] L'invention concerne un groupe de nouveaux dérivés de phénylpipérazine à double mode d'action: inhibition du recaptage de la sérotonine et agonisme partiel à l'égard des récepteurs D2 de la dopamine. L'invention concerne aussi l'utilisation d'un composé décrit en vue de la fabrication d'un médicament produisant un effet bénéfique. Les composés sont représentés par la formule générale (1), dans laquelle les symboles ont les notations données dans la spécification.